Dr Saba emphasizes the prioritizing of rapid BRAF testing and surgical assessment in ATC workups.
Nabil Saba, MD
Advertisement
Nabil Saba, MD, is a widely-recognized expert in immunotherapy for head and neck cancer and upper aero-digestive malignancies at Winship Cancer Institute of Emory University.
Articles by Nabil Saba, MD
ASCO's updated thyroid cancer guidelines help clinicians navigate rapidly evolving systemic therapies, from VEGF inhibitors to BRAF-targeted agents.
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
Early CAR T Brings Questions of Preferred Bridging in Multiple Myeloma
2
Phase 3 Trial of Sacituzumab Govitecan Plus Pembrolizumab Stopped Early in First-Line mNSCLC
3
ASCO 2026 Breast Cancer Highlights: Beyond the LBAs
4
Selinexor Plus Ruxolitinib Improves Spleen Responses, Shows OS Signal in Frontline Myelofibrosis
5